{
    "clinical_study": {
        "@rank": "139589", 
        "acronym": "SYSUCC-002", 
        "arm_group": [
            {
                "arm_group_label": "Palliative chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine."
            }, 
            {
                "arm_group_label": "Palliative endocrine therapy", 
                "arm_group_type": "Experimental", 
                "description": "Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare progression-free survival (PFS) of\n      patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with\n      Trastuzumab Combined With Chemotherapy or Endocrine Therapy."
        }, 
        "brief_title": "Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a non-inferiority study to examine Trastuzumab combined with chemotherapy or\n      endocrine therapy in patients with metastatic Luminal B2 breast cancer subtype. The main\n      purposes of this study are to test the safety and clinical benefit of Trastuzumab combined\n      with chemotherapy or endocrine therapy in treating Luminal B2 breast cancer (hormone\n      receptor positive and human epidermal growth factor receptor (HER2) positive or\n      amplification). This multicentre, randomized study is designed to recruit up to 392 subjects\n      to identify 196 research subjects for each study treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18 years or older.\n\n          2. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.\n\n          3. Histologically confirmed metastatic or local recurrence of breast cancer.\n\n          4. ER positive and/or progesterone receptor (PR) positive, HER-2+ defined as\n             immuno-histochemistry3+ staining or FISH+.\n\n          5. Prior adjuvant Trastuzumab therapy is permitted, but disease-free interval (DFI) must\n             be more than 12 months.\n\n          6. Patients must have measurable or evaluable disease.\n\n          7. Adequate bone marrow reserve with neutrophils > 1000 and platelets > 100,000.\n\n          8. Adequate renal function with serum creatinine < 2.0.\n\n          9. Adequate hepatic reserve with serum bilirubin < 2.0, alanine transaminase(ALT) < 3\n             times the upper limit of normal, and alkaline phosphatase < 5 times the upper limit\n             of normal.\n\n         10. Adequate cardiac reserve with at least 45% of Left ventricular ejection fraction\n             (LVEF) by echocardiogram.\n\n         11. Able to give informed consent.\n\n         12. Life expectancy of at least 12 weeks.\n\n        Exclusion Criteria:\n\n          1. Pregnant or breast feeding.\n\n          2. ECOG score \u22672\n\n          3. DFI <12 months.\n\n          4. LVEF < 45% by echocardiogram.\n\n          5. Uncontrolled medical problems.\n\n          6. Evidence of active acute or chronic infection.\n\n          7. Hepatic, renal, or bone marrow dysfunction as detailed above.\n\n          8. Concurrent malignancy or history of other malignancy within the last five years\n             except as noted above.\n\n          9. Known severe hypersensitivity to Trastuzumab.\n\n         10. Patients were unable or unwilling to comply with program requirements."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "392", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950182", 
            "org_study_id": "SYSUCC-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Palliative endocrine therapy", 
                "description": "Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab", 
                "intervention_name": "Endocrine therapy combined with trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Tamoxifen", 
                    "aromatase inhibitors", 
                    "trastuzumab"
                ]
            }, 
            {
                "arm_group_label": "Palliative chemotherapy", 
                "description": "Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab", 
                "intervention_name": "Chemotherapy combined with trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Capecitabine", 
                    "Vinorelbine", 
                    "Gemcitabine", 
                    "trastuzumab"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tamoxifen", 
                "Gemcitabine", 
                "Vinorelbine", 
                "Trastuzumab", 
                "Capecitabine", 
                "Aromatase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Luminal B2 subtype", 
            "First line treatment"
        ], 
        "lastchanged_date": "September 21, 2013", 
        "location": {
            "contact": {
                "email": "yuanzhygz@163.com", 
                "last_name": "Zhong-yu Yuan, MD", 
                "phone": "86-20-87343794"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype", 
        "overall_contact": {
            "email": "yuanzhy@sysucc.org.cn", 
            "last_name": "Zhong-yu Yuan, MD", 
            "phone": "86-20-87343794"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Zhong-yu Yuan, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The interim analysis and the final analysis are expected ot occur 18 and 36 months after the end of recruitment.", 
            "measure": "progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950182"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Zhong-yu Yuan", 
            "investigator_title": "unYat-senU", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}